Skip to main content
European Commission logo print header

Artificial Intelligence powered epilepsy diagnostics

Project description

Technological advances improve classification of seizure types

The most common serious brain disorder worldwide, epilepsy affects more than 65 million people, including six million in Europe alone. Recent studies show that, if properly treated, up to 70 % of people who suffer from seizures could live productive and fulfilling lives. However, effective treatment hinges on the limitations of current diagnostic methods. Therefore, improving these methods in order to select the best treatment is key. The EU-funded EPINOSTICS project will develop new technology that can automatically detect and classify all motor seizure types and deliver important health benefits globally. The aim is to improve treatment options so that epilepsy is prevented from impairing the physical, psychological and social functioning of those affected.


65 million people globally suffer from epilepsy. The neurological disease causes significant suffering to patients and their caregivers, and its costs in Europe exceed €13 billion annually. Although efficient medications are available, they do not work for 30% of the patients who keep suffering from seizures due to the shortcomings of current epilepsy diagnostics methods. Neurologists need detailed data about seizures to select the best treatment for each patient, but current methods do not provide that data.

Neuro Events Labs is developing an accurate, scalable and affordable solution called ‘Aida’ for epileptic diagnostics, providing neurologists with a comprehensive visual overview of the patients’ seizures. The Aida platform is based on a set of proprietary, patent-pending deep learning algorithms and latest camera technologies. Using these disruptive technologies, Aida detects seizure type, severity and length with unprecedented accuracy and reliability.

The Aida prototype has been piloted in clinical at the Tampere University Hospital to select the best treatment and improve the quality of life of epilepsy patients with outstanding results.

Neuro Event Labs is a venture-backed Finnish SME with a growth-oriented energetic team with extensive experience in building and scaling successful high-tech businesses. Our competences range from business development & sales to 3D cameras, artificial intelligence and neurology.

The EPINOSTICS project allows us to develop capabilities of automatics detection and classification of all motor seizure types and deliver important health benefits globally. The unprecedented functionality allows us to capture a significant portion of the €6.5 billion annual market opportunity. The market is eager for new technologies because the existing methods do not provide satisfactory results.

Call for proposal


See other projects for this call

Sub call


Funding Scheme

SME - SME instrument


Net EU contribution
€ 1 881 250,00
Biokatu 10
33520 Tampere

See on map

Manner-Suomi Länsi-Suomi Pirkanmaa
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 806 250,00